Skye Bioscience Advances Nimacimab Trials with Higher-Dose Expansion Study
Event summary
- Skye Bioscience initiated a higher-dose CBeyond Expansion Study to assess safety and pharmacokinetics of nimacimab at 400 mg and 600 mg IV doses.
- Received FDA Type C meeting minutes to inform Phase 2b combination design elements and potential add-on development path with incretin therapy.
- Presented new body composition data showing differentiated weight maintenance profile for patients discontinuing combination therapy.
- Proof-of-concept preclinical data validated Skye's antigen-peptide conjugate platform, demonstrating additive weight-loss effects.
- Reported $25.7 million in cash, cash equivalents, and short-term investments as of December 31, 2025, expecting to fund operations through Q4 2026.
The big picture
Skye Bioscience is advancing its nimacimab program with a focus on higher-dose evaluations and regulatory alignment, aiming to differentiate its obesity treatment in a competitive market. The company's strategic emphasis on combination therapies and peripheral CB1 inhibition positions it within the broader trend of developing next-generation metabolic health treatments. With $25.7 million in cash reserves, Skye is poised to navigate key clinical milestones but will need to manage financial resources carefully to support late-stage development and potential commercialization.
What we're watching
- Clinical Efficacy
- Whether higher doses of nimacimab in the Expansion Study will achieve targeted weight-loss effects and confirm peripheral exposure-response relationships.
- Regulatory Strategy
- How FDA feedback will shape the Phase 2b trial design and the potential for combination therapy with incretin treatments.
- Financial Runway
- The pace at which Skye Bioscience will need to secure additional funding to support Phase 2b clinical costs and commercial-scale manufacturing.
Related topics